RBCC negotiates potential joint venture with AMBS for traumatic brain injury treatment

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB:RBCC), continues due diligence toward an agreement to help develop a promising new treatment for Traumatic Brain Injury (TBI), concern continues to grow over the troubling incidence of TBI among athletes and soldiers.

The recent, tragic death of NFL great Junior Seau has led to intense speculation that the linebacker suffered from TBI inflicted on the gridiron. Even more disheartening is the number of American war veterans complaining of symptoms as they return from Afghanistan. In recent years, more than 200,000 troops have tested positive for traumatic brain injuries, including concussions.

Currently, TBI and other neuropathic maladies can only be diagnosed after death, leaving many soldiers and athletes to wonder if they have it or not. RBCC hopes to help change that.

The company is currently negotiating a potential joint venture with Amarantus BioSciences (OTCBB: AMBS). AMBS is a biotech firm that has developed a therapeutic protein known as MANF to treat disorders associated with endoplasmic reticulum stress, including traumatic brain injury.

If a definitive agreement is reached, RBCC will help AMBS secure funding to continue their research and development process on a mission to bring a potent new weapon against TBI and other brain afflictions to a global healthcare market hungry for solutions.